MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 533009 | Name: HJC0152
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

HJC0152 is a signal transducer and activator of transcription 3 (STAT3) inhibitor against human head and neck squamous cell carcinoma (HNSCC).

Chemical Structure

HJC0152
HJC0152
CAS#1420290-99-8

Theoretical Analysis

MedKoo Cat#: 533009

Name: HJC0152

CAS#: 1420290-99-8

Chemical Formula: C15H14Cl3N3O4

Exact Mass: 405.0050

Molecular Weight: 406.64

Elemental Analysis: C, 44.31; H, 3.47; Cl, 26.15; N, 10.33; O, 15.74

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,350.00 2 Weeks
500mg USD 2,650.00 2 Weeks
1g USD 3,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
HJC0152; HJC 0152; HJC-0152.
IUPAC/Chemical Name
2-(2-Amino-ethoxy)-5-chloro-N-(2-chloro-4-nitrophenyl)benzamide Hydrochloride
InChi Key
XRZHLOYBZOONSZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H13Cl2N3O4.ClH/c16-9-1-4-14(24-6-5-18)11(7-9)15(21)19-13-3-2-10(20(22)23)8-12(13)17;/h1-4,7-8H,5-6,18H2,(H,19,21);1H
SMILES Code
O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2OCCN.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
HJC0152 hydrochloride is a signal transducers and activators of transcription 3 (STAT3) inhibitor.
In vitro activity:
As shown in Figure Figure1C‐E, HJC0152 showed a significant inhibitory effect that was both concentration‐ and time‐dependent. The IC50 values of HJC0152 against A549, H460 and H1299 cells were 5.11, 5.01 and 13.21 μmol/L, respectively (Figure 1F‐H). These findings suggest that HJC0152 has a strong cytostatic and cytotoxic effect on NSCLC cells and that NSCLC cells with higher p‐STAT3 (Tyr705) levels are more sensitive to HJC0152. Reference: Cell Prolif. 2020 Mar;53(3):e12777. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106968/
In vivo activity:
To determine the anti-tumor effect of HJC0152 in vivo, nude mice were subcutaneously inoculated with MKN45 cells and treated with HJC0152 (7.5 mg/kg) or PBS. As exhibited in Figure 3A–C, the tumor volumes (P<0.001) and tumor weight (P<0.01) were significantly lower in the HJC0152-treated group compared with the control group. Reference: Cancer Manag Res. 2018 Dec 12;10:6857-6867. https://pubmed.ncbi.nlm.nih.gov/30588091/
Solvent mg/mL mM
Solubility
DMF 0.1 0.25
DMSO 30.3 74.59
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 406.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Lu L, Li H, Wu X, Rao J, Zhou J, Fan S, Shen Q. HJC0152 suppresses human non-small-cell lung cancer by inhibiting STAT3 and modulating metabolism. Cell Prolif. 2020 Mar;53(3):e12777. doi: 10.1111/cpr.12777. Epub 2020 Feb 5. PMID: 32022328; PMCID: PMC7106968. 2. Li Z, Zhu T, Xu Y, Wu C, Chen J, Ren Y, Kong L, Sun S, Guo W, Wang Y, Jing C, Dong J, Zhou J, Zhang L, Shen Q, Zhou X. A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma. Am J Cancer Res. 2019 Apr 1;9(4):699-713. PMID: 31105997; PMCID: PMC6511646. 3. Jiang X, Wu M, Xu Z, Wang H, Wang H, Yu X, Li Z, Teng L. HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer. Cancer Manag Res. 2018 Dec 12;10:6857-6867. doi: 10.2147/CMAR.S188364. PMID: 30588091; PMCID: PMC6296682. 4. Wang Y, Wang S, Wu Y, Ren Y, Li Z, Yao X, Zhang C, Ye N, Jing C, Dong J, Zhang K, Sun S, Zhao M, Guo W, Qu X, Qiao Y, Chen H, Kong L, Jin R, Wang X, Zhang L, Zhou J, Shen Q, Zhou X. Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152. Mol Cancer Ther. 2017 Apr;16(4):578-590. doi: 10.1158/1535-7163.MCT-16-0606. Epub 2017 Jan 30. PMID: 28138036; PMCID: PMC5380531.
In vitro protocol:
1. Lu L, Li H, Wu X, Rao J, Zhou J, Fan S, Shen Q. HJC0152 suppresses human non-small-cell lung cancer by inhibiting STAT3 and modulating metabolism. Cell Prolif. 2020 Mar;53(3):e12777. doi: 10.1111/cpr.12777. Epub 2020 Feb 5. PMID: 32022328; PMCID: PMC7106968. 2. Li Z, Zhu T, Xu Y, Wu C, Chen J, Ren Y, Kong L, Sun S, Guo W, Wang Y, Jing C, Dong J, Zhou J, Zhang L, Shen Q, Zhou X. A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma. Am J Cancer Res. 2019 Apr 1;9(4):699-713. PMID: 31105997; PMCID: PMC6511646.
In vivo protocol:
1. Jiang X, Wu M, Xu Z, Wang H, Wang H, Yu X, Li Z, Teng L. HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer. Cancer Manag Res. 2018 Dec 12;10:6857-6867. doi: 10.2147/CMAR.S188364. PMID: 30588091; PMCID: PMC6296682. 2. Wang Y, Wang S, Wu Y, Ren Y, Li Z, Yao X, Zhang C, Ye N, Jing C, Dong J, Zhang K, Sun S, Zhao M, Guo W, Qu X, Qiao Y, Chen H, Kong L, Jin R, Wang X, Zhang L, Zhou J, Shen Q, Zhou X. Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152. Mol Cancer Ther. 2017 Apr;16(4):578-590. doi: 10.1158/1535-7163.MCT-16-0606. Epub 2017 Jan 30. PMID: 28138036; PMCID: PMC5380531.
1: Wang Y, Wang S, Wu Y, Ren Y, Li Z, Yao X, Zhang C, Ye N, Jing C, Dong J, Zhang K, Sun S, Zhao M, Guo W, Qu X, Qiao Y, Chen H, Kong L, Jin R, Wang X, Zhang L, Zhou J, Shen Q, Zhou X. Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152. Mol Cancer Ther. 2017 Apr;16(4):578-590. doi: 10.1158/1535-7163.MCT-16-0606. Epub 2017 Jan 30. PubMed PMID: 28138036; PubMed Central PMCID: PMC5380531.

View History

BB-0300674

BB-0300674